RNAZ

Companies
NASDAQ
Transcode Therapeutics Inc.
Health Care
Price Chart
Overview

About RNAZ

transcode therapeutics is a boston based pre-clinical biopharmaceutical company focused on discovery, development and commercialization of a pipeline of innovative microrna (mirnas or mirs) therapeutics for treating metastatic disease.

Market Cap
$7.3M
Volume
42.9M
Avg. Volume
81.1M
P/E Ratio
-0.7416666
Dividend Yield
0.00%
Employees
13.0

Company Information

Exchange
NASDAQ
Sector
Health Care
Industry
Biotechnology
Risk & Correlation Analysis
Market Correlation
0.68
Low Correlation
Volatility
High (1.00)
Relative to market

Macro Factor Sensitivities

Interest Rates
Low Sensitivity
Inflation
Low Sensitivity
GDP Growth
High Sensitivity
Liquidity
Low Sensitivity
Commodity Prices
Medium Sensitivity
Credit Quality
Medium Sensitivity
Portfolio Impact
Forecasts & Predictions

Premium Forecasts

Get AI-powered price predictions, technical analysis, and market forecasts for RNAZ.

1-Month Target
$XXX.XX
+X.X% Potential
3-Month Target
$XXX.XX
+X.X% Potential
12-Month Target
$XXX.XX
+X.X% Potential

Technical Analysis

Based on technical indicators and chart patterns, RNAZ shows...

AI Sentiment Analysis

Market sentiment analysis indicates...

Key Statistics
Market Cap$7.3M
Volume42.9M
P/E Ratio-0.74
Dividend Yield0.00%
Important Dates
Next Dividend
Next Earnings
November 14, 2023
Related Securities

PortfolioPilot Analysis

Get AI-powered insights on how RNAZ fits into your investment strategy and portfolio diversification.

Pricing info last updated June 18, 2025 (after market close)Other info last updated April 2, 2025